Anna A. Kosova
Research Subjects
Anna A. Kosova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aishan Е. Ibaduiiaeva
Pavlov First St. Petersburg State Medical University
1 shared publication - Anastaiya N. Nikovaeva
Novgorod State University
1 shared publication - Anastasiya V. Fayans
Pirogov Russian National Research Medical University
1 shared publication - Dayana G. Bajburdyan
Pavlov First St. Petersburg State Medical University
1 shared publication - Dmitriy V. Kaiinin
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication - Eieonora Yu. Ivanova
Voronezh State Medical University named after N.N. Burdenko
1 shared publication
Latest Publications
- Open Access
- 26 December 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (6) , 520-533
Modern Possibilities of Usage Dupilumab in Children
Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.
- 26 December 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (6) , 520-533
Open AccessModern Possibilities of Usage Dupilumab in Children
Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.